Novartis MS treatment cuts relapse rates by a third in pivotal trials

· Health · Switzerland

A multiple sclerosis treatment from Novartis cut relapse rates by a third compared with a standard treatment in pivotal trials, STAT reported. Multiple sclerosis is a chronic neurological disease in which the immune system attacks the protective coating of nerve cells, and relapse rate is a core measure of how well a therapy controls disease activity. The results position the Novartis candidate against established standard-of-care treatments, a crowded area where several drugmakers are competing. The report arrived on the same day that STAT published commentary on misdiagnosis in MS, following actress Christina Applegate's public discussion of her condition. If the data hold up, they could support a regulatory filing and eventually shift treatment choices for relapsing forms of the disease.

Why it matters：A one-third relapse reduction would give Novartis a competitive claim in a crowded MS market and could influence how physicians sequence therapies for relapsing disease.

Key points

  • The comparison was against a standard treatment in pivotal trials.
  • Relapse rate is a core efficacy measure in relapsing multiple sclerosis.
  • STAT reported the results on the same day it published MS commentary pieces.

Sources (original reporting)

More stories from this day